Voice your opinion on congressional bill HR4106-116 and let lawmakers know your stance with UnPac!

Main Subject: Health

Responsibility in Drug Advertising Act of 2019

This bill prohibits direct-to-consumer advertising of a drug in the first three years after the drug's approval. The Food and Drug Administration may (1) waive the third year of this prohibition for a drug if direct-to-consumer advertising of the drug would have an affirmative value to public health, or (2) extend the prohibition if the drug has significant adverse health effects.

HR2452-116, S3180-116,

House committee actions Actions

Committee
Jul. 31 2019	Referred to the Subcommittee on Health.

House floor actions Actions

IntroReferral
Jul. 30 2019	Referred to the House Committee on Energy and Commerce.

Library of Congress Actions

IntroReferral
Jul. 30 2019	Introduced in House Introduced in House

House bill HR4106-116

Responsibility in Drug Advertising Act of 2019

Promote the cause!

Or use this QR code